Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2015 07:30 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting

NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the presentation of new data from the IMPACT...
February 26, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Appoints Avner Ingerman, M.D. as Chief Clinical Officer

NEW YORK, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an Ophthalmology research and development company, today announced the appointment of Avner Ingerman, MD, to the...
February 11, 2015 12:54 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock

NEW YORK, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it has closed its previously announced...
February 09, 2015 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Fiscal First Quarter 2015 Financial and Business Results

NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its first fiscal quarter ended December...
February 09, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the 17th Annual BIO CEO & Investor Conference and Leerink Global Healthcare Conference in New York

NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
February 06, 2015 08:30 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Prices $25,000,000 Public Offering of Common Stock

NEW YORK, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced the pricing of its previously announced underwritten...
February 05, 2015 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock

NEW YORK, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it intends to offer its common stock in an...
January 08, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Appoints Jason Slakter, MD, Chief Medical Officer, to Board of Directors

NEW YORK, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Jason Slakter, MD, Chief Medical Officer, has...
December 22, 2014 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Fiscal Year 2014 Financial and Business Results

NEW YORK, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its fiscal year ended September 30,...
December 19, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Announce Fiscal 2014 Financial Results and Host Conference Call on Monday, December 22

NEW YORK, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced that it will report its...